-
Mashup Score: 5FDA approves idecabtagene vicleucel for triple-class-exposed RRMM - 1 month(s) ago
On April 5, 2024, the U.S. FDA granted approval to idecabtagene vicleucel for the treatment of triple-class-exposed relapsed/refractory multiple myeloma after two or more prior therapies, including an immunomodulatory agent, proteasome inhibitor, and an anti-CD38 antibody.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5European Commission approves idecabtagene vicleucel for the treatment of triple-class-exposed RRMM - 2 month(s) ago
On March 20, 2024, the European Commission granted approval to ide-cel for the treatment of triple-class-exposed RRMM with two or more prior therapies, including an IMiD, PI, and an anti-CD38 antibody with subsequent disease progression.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma SAN DIEGO and SUZHOU, China and SHANGHAI, China, Jan. 29, 2024 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc.
Source: ir.gracellbio.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11
The U.S. FDA grants orphan drug designation to BeiGene’s sonrotoclax for relapsed/refractory multiple myeloma treatment.
Source: seekingalpha.comCategories: General Medicine News, Onc News and JournalsTweet
🚨 NEWS 🚨 @US_FDA grants approval to idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, for the treatment of triple-class-exposed relapsed/refractory #MultipleMyeloma Read more: https://t.co/rM9RaqFJfa #mmsm #myeloma #MedNews https://t.co/hX3OtuRLEU